Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American...
Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the...
MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...
Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and...
Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 ...
After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of...
MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...
Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA...
MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...
Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the...